238 related articles for article (PubMed ID: 12040668)
21. Phenotyping of drug metabolism in infants and children: potentials and problems.
Rane A
Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
[No Abstract] [Full Text] [Related]
22. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of cytochromes P450.
Hasler JA
Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
[No Abstract] [Full Text] [Related]
24. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
[TBL] [Abstract][Full Text] [Related]
26. Association between CYP2A6 and CYP2C19 mutant alleles.
Lam K; Chow L; Leung T; Wing YK; Chiu HF; Garcia-Barceló M
Clin Pharmacol Ther; 1999 Dec; 66(6):647. PubMed ID: 10613622
[No Abstract] [Full Text] [Related]
27. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
28. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics: role in modifying drug dosage regimens.
Mah JT; Wong JY; Lee EJ
Ann Acad Med Singap; 2000 Sep; 29(5):628-32. PubMed ID: 11126699
[TBL] [Abstract][Full Text] [Related]
30. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
31. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
32. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
33. [Association between genetic polymorphism and lung cancer risk].
Ariyoshi N; Kitada M; Kamataki T
Nihon Rinsho; 2002 May; 60 Suppl 5():46-9. PubMed ID: 12101715
[No Abstract] [Full Text] [Related]
34. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
Inoue K; Yamazaki H; Shimada T
Xenobiotica; 1998 Apr; 28(4):403-11. PubMed ID: 9604303
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
Wojtczak A; Skretkowicz J
Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
[TBL] [Abstract][Full Text] [Related]
36. [Genotyping of CYP2D6 and CYP2C19].
Slanar O; Drazd'áková M; Babiárová K; Pechandová K; Buzková H; Perlík F; Zima T
Cas Lek Cesk; 2007; 146(9):708-11. PubMed ID: 17966194
[TBL] [Abstract][Full Text] [Related]
37. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population.
Yamada H; Dahl ML; Lannfelt L; Viitanen M; Winblad B; Sjöqvist F
Eur J Clin Pharmacol; 1998 Aug; 54(6):479-81. PubMed ID: 9776439
[TBL] [Abstract][Full Text] [Related]
38. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
Bajpai M; Roskos LK; Shen DD; Levy RH
Drug Metab Dispos; 1996 Dec; 24(12):1401-3. PubMed ID: 8971149
[No Abstract] [Full Text] [Related]
39. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
Masimirembwa CM; Hasler JA
Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
[TBL] [Abstract][Full Text] [Related]
40. Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H; Lubetsky A
Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
